Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer
Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
PSMA-Based Imaging and Theranostics: A Summary of Current Paradigm Shifts and a Look to the Future
The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.
Unmet Needs in Imaging for Patients With Prostate Cancer
Drs Cookson and Sellinger discuss the remaining unmet needs in imaging for patients with prostate cancer.
Navigating Virtual Tumor Boards for Prostate Cancer PSMA-PET Imaging
The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.
Best Practices for Communication: A Multidisciplinary Perspective
Delving deeper into PSMA-PET results interpretation and information sharing, panelists outline the most critical information needed from radiologists and urologists on a patient’s multidisciplinary care team.
Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation
Experts share potential solutions to overcome the clinical challenges of using PSMA-PET in practice, including use of reader training programs.
Challenges of Implementing PSMA-Targeted PET Imaging in Prostate Cancer
Dr Cookson discusses the challenges of using PSMA-PET imaging in prostate cancer, including reimbursement and patient access.
Overview of Available Clinical Guidelines on PSMA-PET Imaging in Prostate Cancer
Dr Sellinger details the range of clinical guidelines on the use of PSMA-PET imaging in prostate cancer and which he is most likely to follow.
Impact of PSMA-Targeted Imaging Modalities on Management of Prostate Cancer
The panel reviews clinical data and provides real-world insight on how use of PSMA-PET imaging has impacted the management of patients with prostate cancer.
Practical Considerations for Selection of PSMA-PET Tracers
Experts discuss practical considerations on selection among available PSMA-PET tracer options for prostate cancer imaging, including regional availability, scheduling, and preparation requirements.
Approved PSMA-PET Imaging Tracer Options for Prostate Cancer
The panel reviews the similarities and differences between the FDA-approved PSMA-PET tracer options for prostate cancer imaging.
Introduction to PSMA-Targeted PET Imaging
Phillip Koo, MD, defines prostate-specific membrane antigen (PSMA) and explains the rationale for use as a target in PET-based prostate cancer imaging.
Conventional Imaging for Prostate Cancer
Scott Sellinger, MD, FACS, shares a historical perspective on use of conventional imaging modalities in prostate cancer.
Risk Stratification of Patients with Prostate Cancer
Michael Cookson, MD, MMHC, explains the NCCN criteria used to stratify patients with clinically localized prostate cancer into risk groups.
2 Clarke Drive Cranbury, NJ 08512